ABYSS Trial: No Difference in Outcomes Continuing or Stopping Beta-Blockers Following MI
The ABYSS trial suggests continuing beta-blockers may not be necessary for post-MI patients with preserved ejection fraction, but further research is needed. Results showed no safety preservation or quality of life benefits with beta-blocker interruption, with similar rates of death, MI, and stroke between groups, but higher rates of cardiovascular hospitalizations in the interruption group.
Reference News
The ABYSS trial suggests continuing beta-blockers may not be necessary for post-MI patients with preserved ejection fraction, but further research is needed. Results showed no safety preservation or quality of life benefits with beta-blocker interruption, with similar rates of death, MI, and stroke between groups, but higher rates of cardiovascular hospitalizations in the interruption group.